Tarsus Pharmaceuticals, Inc. (TARS)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-01-14

Key Insights

  • The reporting person, Katherine Goodrich, exercised 2,233 restricted stock units (RSUs) on 12/15/2025, indicating their continued ownership and vesting of company equity.
  • The RSUs have a 3-year vesting schedule, with additional tranches vesting in 2026 and 2027, aligning the reporting person's incentives with long-term company performance.
  • The reporting person's direct ownership of Tarsus Pharmaceuticals, Inc. (TARS) shares increased to 2,233 following the RSU exercise, suggesting they maintain a meaningful stake in the company.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Tarsus Pharmaceuticals, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.